Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA7 | P43166 | 1/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4724826 | 0.79 | CA12 (1.00) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL9544274 | 0.77 | — | — | |
| SCHEMBL490315 | 0.77 | CA12 (0.65) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL222875 | 0.77 | CA12 (0.65) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL12856096 | 0.74 | CA12 (0.62) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL171195 | 0.74 | CA12 (0.62) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL14160309 | 0.74 | CA12 (0.62) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL16692519 | 0.74 | CA12 (0.62) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL302386 | 0.74 | CA12 (0.62) | CA12CA7CA14SMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL29968774 | 0.74 | CA12 (0.62) | CA12CA7CA14SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4011208-A | 3-CYANO OR ACYL-4-ARYL-5-ARYLAZO-6-HYDROXYPYRIDONE-2 DYES | SANDOZ LTD. (CH) | 1977-03-08 | — | — | US | claimed |
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-29 | — | — | US | disclosed |
| US-20210052550-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-02-25 | — | — | US | disclosed |
| EP-3698788-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-08-26 | — | — | EP | disclosed |
| US-10646468-B2 | Composition comprising tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-05-12 | — | — | US | disclosed |
| EP-3613729-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-02-26 | — | — | EP | disclosed |
| EP-2606886-B1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-01-08 | — | — | EP | disclosed |
| EP-3345903-B1 | TETRACYCLIC COMPOUNDS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2019-10-09 | — | — | EP | disclosed |
| US-8901302-B2 | Pyrazino[2,3-D]isoxazole derivative which is useful as a production intermediate of pyrazine carboxamide derivative | FUJIFILM CORPORATION (JP) | 2014-12-02 | — | — | US | disclosed |
| CN-103347884-A | Pyrazino[2,3-d]isooxazole derivative | FUJI PHOTO FILM CO LTD | 2013-10-09 | — | — | CN | disclosed |
| US-20130245264-A1 | PYRAZINO[2,3-D]ISOXAZOLE DERIVATIVE | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-19 | — | — | US | disclosed |
| EP-2639235-A1 | PYRAZINO[2,3-D]ISOOXAZOLE DERIVATIVE | FUJIFILM Corporation (JP) | 2013-09-18 | — | — | EP | disclosed |
| EP-2606886-A1 | COMPOSITION CONTAINING TETRACYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-20130143877-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-06-06 | — | — | US | disclosed |
| CN-102459172-A | Tetracyclic compounds | CHUGAI PHARMACEUTICAL CO LTD | 2012-05-16 | — | — | CN | disclosed |
| EP-2441753-A1 | TETRACYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
| US-4011208-A | 3-CYANO OR ACYL-4-ARYL-5-ARYLAZO-6-HYDROXYPYRIDONE-2 DYES | SANDOZ LTD. (CH) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143877-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | CA12 614/4885CA7 555/4885CA14 264/4885 |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | CA12 346/4885CA7 332/4885CA14 230/4885 |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | CA12 346/4885CA7 332/4885CA14 230/4885 |
| US-20130245264-A1 | PYRAZINO[2,3-D]ISOXAZOLE DERIVATIVE | XDH, SQOR, NPY5R | CA12 1525/4885CA7 689/4885CA14 2032/4885 |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | CA12 346/4885CA7 332/4885CA14 230/4885 |
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | CA12 614/4885CA7 555/4885CA14 264/4885 |
| US-20210052550-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | CA12 614/4885CA7 555/4885CA14 264/4885 |
| US-10646468-B2 | Composition comprising tetracyclic compound | ALK, ALPI, TTR | CA12 614/4885CA7 555/4885CA14 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.